Log in or Sign up for Free to view tailored content for your specialty!
Ophthalmology News
VIDEO: Johnson & Johnson Vision shares update on cataract, refractive armamentarium
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Xiao-Yu Song, MD, PhD, of Johnson & Johnson Vision, gives an overview of company innovations for improving vision outcomes in refractive and cataract surgery.
VIDEO: EYP-1901 shows positive vision, treatment burden outcomes at 1 year
CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Carl D. Regillo, MD, FACS, of Wills Eye Hospital, shares study results from the phase 2 DAVIO 2 trial.
Log in or Sign up for Free to view tailored content for your specialty!
VIDEO: Consider epithelial thickness mapping during refractive cataract surgery planning
NEW YORK — In this Healio Video Perspective from OSN New York, John P. Berdahl, MD, shares pearls on how to decide between LASIK or PRK for patients who previously underwent cataract surgery.
AlloVir to merge with Kalaris Therapeutics
AlloVir, an allogeneic T cell immunotherapy company, will merge with Kalaris Therapeutics to focus on retinal diseases, according to a press release.
VIDEO: Ocular Therapeutix shifts to retina-focused treatments
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses the company’s shift to a retina-focused program.
Optogenetic therapy holds promise for treatment of late-stage geographic atrophy
BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Jordi Monés, MD, PhD, discusses an investigational optogenetic therapy for geographic atrophy.
VIDEO: Dextenza shows promising IOP outcomes in patients with glaucoma
NEW YORK — In this Healio Video Perspective from OSN New York, Nandini Venkateswaran, MD, of Massachusetts Eye and Ear Infirmary, discusses real-world data investigating the use of Dextenza in patients with glaucoma.
BLOG: What would you risk for a miracle?
What risks should we accept in exchange for a miracle?
FDA extends Prescription Drug User Fee Act date for macular telangiectasia type 2 therapy
The FDA has extended its Prescription Drug User Fee Act date for the biologics license application for NT-501, a treatment for macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.
What specific risk factors do you discuss with patients who are prescribed GLP-1 agonists?
Recent research has suggested that GLP-1 agonists used to treat obesity might be associated with a stroke in the optic nerve, but association is not the same as causation.
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read